A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis

Carlin, Christopher S.; Feldman, Steven R.; Krueger, James G.; Menter, Alan; Krueger, Gerald G.

doi:10.1016/j.jaad.2003.09.014

Cited by 256 publications

(200 citation statements)

References 45 publications

(36 reference statements)

Supporting

Mentioning

184

Contrasting

Unclassified

Order By: Relevance

“…1 Most cases are benign and recurrent, but the disease can be physically or socially debilitating. 2 The Psoriasis Area Severity Index (PASI) is a tool developed in 1978 by Fredricksson and Pettersson to evaluate the severity of psoriasis. This index analyzes the four regions of the body (head, trunk, upper and lower limbs) in relation to erythema, induration (thickness), desquamation (scaling) of the plaques, and body surface area (BSA) affected.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Importância da variação do PASI realizado por diversos observadores

Faria

Aarão

Jimenez

et al. 2010

An. Bras. Dermatol.

View full text Add to dashboard Cite

BACKGROUND: Developed in 1978, the PASI (Psoriasis Area and Severity Index) is a method to rate psoriasis severity. Since then, it has been criticized for being extremely long, complex and for yielding significantly divergent interpretations. OBJECTIVE: To determine the PASI inter-rater reliability among three independent evaluators examining the same patients. METHODS: Cross-sectional study conducted in 2007 at a psoriasis treatment center, where 20 patients were selected. The patients were evaluated by three postgraduate students of Dermatology who independently determined the PASI of each patient. The inter-rater reliability coefficient was determined by employing intraclass correlation coefficients (ICC)

show abstract

Section: Introductionmentioning

confidence: 99%

“…2 The PASI scores that classify psoriasis as severe vary constantly. To some authors, the severity of the PASI has been defined as ≥ 18, while others suggest ≥ 12.…”

Section: Introductionmentioning

confidence: 99%

Importância da variação do PASI realizado por diversos observadores

Faria

Aarão

Jimenez

et al. 2010

An. Bras. Dermatol.

View full text Add to dashboard Cite

show abstract

“…Countries have unpredictable social security systems and compensation charges so direct comparison between studies has been considered problematic (Raho et al, 2012;Schöffski et al, 2007;Carrascosa et al, 2006). The medication costs to patients in this study may not be directly generalizable to other countries as it is not based on national policy as India does not have a standard healthcare system that can be compared to the rest of the countries.…”

Section: Discussionmentioning

confidence: 99%

“…In this study the treatment options that we have considered are patients on phototherapy with topical or systemic agents with topical therapy only.The cost of illness was computed as these treatments are the benchmark for physicians and patients, which is based on the systemic side effects profile of the drugs as well as the PASI score (Carlin et al, 2004).…”

Section: * Corresponding Authormentioning

confidence: 99%

“…The therapeutic treatment of psoriasis is mainly guided by the stages of psoriasis which is based on psoriasis area severity index (PASI) score. The PASI score categorizes psoriasis into mild, moderate and severe (Carlin CS et al, 2004). The treatment options available include topical steroids, coal tar application, oral methotrexate, retinoids, cyclosporine, UVB phototherapy and photochemotherapy (PUVA).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Cost of illness in psoriasis patients on Bath PUVA therapy versus Methotrexate

Satheendran¹,

Nagappa²,

Rajan

et al. 2016

J App Pharm Sci

View full text Add to dashboard Cite

Psoriasis results in expenses to patients from many cost sources. Psoriasis treatment may result in considerable time and travelling costs, yet many studies fail to account for these costs. The objective of this study was to evaluate the economic burden of psoriasis in patients. Methods: The study was based on 200 patients with psoriasis visiting a tertiary level dermatological clinic. The data was based on a patient questionnaire and clinical data from the medical records. Item costs were based on true costs charged from the patients and all time cost estimates were done. Results: 200 patients with psoriasis were included in the study. Total costs were higher for patients receiving phototherapy than those receiving systemic treatment. The majority of the visit costs arose from hospitalization and only a small proportion were attributed to outpatient visits. Conclusion: Visit charges and other patient investigations were estimated to play a minor role in the total cost of psoriasis incurred by patients, while travel costs and loss of pay comprised the majority of the costs, which should not be omitted in future studies regarding costs of treatments.

show abstract